Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study

Journal of Dermatology

Volumn 43, Issue 8, 2016, Pages 869-880

  Asahina, Akihiko ^a   Etoh, Takafumi ^b   Igarashi, Atsuyuki ^c   Imafuku, Shinichi ^d   Saeki, Hidehisa ^e   Shibasaki, Yoshiyuki ^f   Tomochika, Yukiko ^f   Toyoizumi, Shigeyuki ^f   Nagaoka, Makoto ^f   Ohtsuki, Mamitaro ^g  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO TEISHIN HOSPITAL   (Japan)

^c Nippon Telegraph and Telephone Corporation Medical Center Tokyo   (Japan)

^d FUKUOKA UNIVERSITY   (Japan)

^e NIPPON MEDICAL SCHOOL   (Japan)

^f PFIZER INC   (United States)

^g JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Japan; kinase inhibitor; plaque psoriasis; psoriatic arthritis; tofacitinib

Indexed keywords

BETAMETHASONE; CELECOXIB; CREATINE KINASE; FEXOFENADINE; HEMOGLOBIN; HYDROCORTISONE; LEVOCETIRIZINE; TOFACITINIB;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CRITERION VARIABLE; DISEASE DURATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLOBAL ASSESSMENT OF FUNCTIONING; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HUMAN; IMMUNOGENICITY; INFLUENZA; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TERATOGENICITY; TINEA PEDIS; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84980374237     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.13258     Document Type: Article

References (55)

1. Gudjonsson JE, Elder JT. Psoriasis. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller A, Leffell DJ, Wolff K, eds. Fitzpatrick's Dermatology in General Medicine, 8th edn. New York: McGraw-Hill Medical, 2012; 197–232.
2. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005; 352: 1899–1912.
3. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401–407.
4. Kubota K, Kamijima Y, Sato T et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open 2015; 5: e006450.
5. Gelfand JM, Stern RS, Nijsten T et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52: 23–26.
6. Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377–385.
7. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 2014; 70: 512–516.
8. Takahashi H, Nakamura K, Kaneko F, Nakagawa H, Iizuka H. Analysis of psoriasis patients registered with the Japanese Society for Psoriasis Research from 2002-2008. J Dermatol 2011; 38: 1125–1129.
9. Ohara Y, Kishimoto M, Takizawa N et al. Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. J Rheumatol 2015; 42: 1439–1442.
10. Asahina A, Nakagawa H, Etoh T, Ohtsuki M. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled study. J Dermatol 2010; 37: 299–310.
11. Igarashi A, Kato T, Kato M, Song M, Nakagawa H. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012; 39: 242–252.
12. Ohtsuki M, Morita A, Abe M et al. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study. J Dermatol 2014; 41: 1039–1046.
13. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. J Dermatol Sci 2010; 59: 40–49.
14. Ohtsuki M, Terui T, Ozawa A et al. Japanese guidance for use of biologics for psoriasis (the 2013 version). J Dermatol 2013; 40: 683–695.
15. Hsu S, Papp KA, Lebwohl MG et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012; 148: 95–102.
16. Weger W. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents. Br J Pharmacol 2010; 160: 810–820.
17. Halioua B, Saurat JH. Risk: benefit ratio in the treatment of psoriasis with systemic retinoids. Br J Dermatol 1990; 122(Suppl 36): 135–150.
18. Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA Follow-Up Study. N Engl J Med 1997; 336: 1041–1045.
19. Studniberg HM, Weller P. PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 1993; 29: 1013–1022.
20. Weinberg JM. An overview of infliximab, etanercept, efalizumab, and alefacept as biologic therapy for psoriasis. Clin Ther 2003; 25: 2487–2505.
21. Zisapel M, Zisman D, Madar-Balakirski N et al. Prevalence of TNF-alpha Blocker Immunogenicity in Psoriatic Arthritis. J Rheumatol 2015; 42: 73–78.
22. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 152: 597–615.
23. Umar N, Schaarschmidt M, Schmieder A, Peitsch WK, Schollgen I, Terris DD. Matching physicians' treatment recommendations to patients' treatment preferences is associated with improvement in treatment satisfaction. J Eur Acad Dermatol Venereol 2013; 27: 763–770.
24. Torii H, Nakagawa H. Questionnaire survey of perceived satisfaction with treatment of patients with psoriasis. Jpn J Dermatol 2013; 123: 1935–1944.
25. Lebwohl MG, Bachelez H, Barker J et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014; 70: 871–881.
26. Papp KA, Menter A, Strober B et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668–677.
27. Bachelez H, van de Kerkhof PCM, Strohal R et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015; 386: 552–561.
28. Bissonnette R, Iversen L, Sofen H et al. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. Br J Dermatol 2015; 172: 1395–1406.
29. Papp KA, Menter A, Abe M et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 2015; 173: 949–961.
30. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665–2673.
31. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003; 49: 206–212.
32. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.
33. Saurat JH, Stingl G, Dubertret L et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558–566.
34. Papp K, Cather JC, Rosoph L et al. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738–746.
35. Papp KA, Kaufmann R, Thaci D, Hu C, Sutherland D, Rohane P. Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. J Eur Acad Dermatol Venereol 2013; 27: e376–e383.
36. Reich K, Nestle FO, Papp K et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367–1374.
37. Gordon KB, Langley RG, Leonardi C et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006; 55: 598–606.
38. Leonardi CL, Kimball AB, Papp KA et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008; 371: 1665–1674.
39. Papp KA, Langley RG, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675–1684.
40. Langley RG, Elewski BE, Lebwohl M et al. Secukinumab in plaque psoriasis–results of two phase 3 trials. N Engl J Med 2014; 371: 326–338.
41. Kavanaugh A, Mease PJ, Gomez-Reino JJ et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 2014; 73: 1020–1026.
42. Schett G, Wollenhaupt J, Papp K et al. Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2012; 64: 3156–3167.
43. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009; 60: 976–986.
44. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005; 52: 3279–3289.
45. Ritchlin C, Rahman P, Kavanaugh A et al. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014; 73: 990–999.
46. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004; 50: 2264–2272.
47. Kavanaugh A, Krueger GG, Beutler A et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis 2007; 66: 498–505.
48. Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol 2015; 25: 514–521.
49. Basra MK, Salek MS, Camilleri L, Sturkey R, Finlay AY. Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. Br J Dermatol 2015; 230: 27–33.
50. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg 2009; 13(Suppl 2): S102–S106.
51. Krueger J, Suarez-Farinas M, Fuentes-Duculan J et al. Pathologic immune pathways in psoriasis are rapidly attenuated by tofacitinib treatment. Br J Dermatol 2014; 171: e120.
52. Winthrop KL, Yamanaka H, Valdez H et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2014; 66: 2675–2684.
53. Winthrop K, Lebwohl M, Cohen AD et al. Herpes zoster and tofacitinib therapy in patients with psoriasis. J Invest Dermatol 2015; 135: S1.
54. Yamaoka K, Tanaka Y, Morishima Y et al. Herpes zoster and tofacitinib therapy in Japanese patients with rheumatoid arthritis. Japan College of Rheumatology – 59th Annual Scientific Meeting 2015; 25: S96.
55. Toyama N, Shiraki K. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48 388 herpes zoster cases in Miyazaki prefecture. J Med Virol 2009; 81: 2053–2058.